SML2702
ST045849
≥98% (HPLC)
别名:
2-[(4-Chlorophenyl)imino]tetrahydro-4-oxo-3-(2-tricyclo[3.3.1.13,7]dec-1-ylethyl)-2H-1,3-thiazine-6-carboxylic acid, 3-(2-Adamantanylethyl)-2-[(4-chlorophenyl)azamethylene]-4-oxo-l,3-thiazaperhyd roine-6-carboxylic acid, TT04
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
Assay:
≥98% (HPLC)
Form:
powder
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
SMILES string
O=C(N/1CCC23C[C@H](C4)C[C@H](C[C@H]4C3)C2)CC(SC1=N/C5=CC=C(C=C5)Cl)C(O)=O
InChI
1S/C23H27ClN2O3S/c24-17-1-3-18(4-2-17)25-22-26(20(27)10-19(30-22)21(28)29)6-5-23-11-14-7-15(12-23)9-16(8-14)13-23/h1-4,14-16,19H,5-13H2,(H,28,29)/b25-22-/t14-,15+,16-,19?,23?
InChI key
HLPZEZRNGAXCJH-QLAUEMIBSA-N
Biochem/physiol Actions
O-GlcNAc transferase (OGT) inhibitor with in vitro and in vivo efficay.
ST045849 (TT04) is an O-GlcNAc transferase (OGT) Inhibitor (IC50/human splice variant = 30 μM/sOGT & 53 μM/ncOGT; 6.25 μM UDP-GlcNAc, 500 μM peptide substrate KKKYPGGSTPVSSANMM). ST045849 is typically employed in the 1-100 μM range for probing O-GlcNAcylation-dependent cellular processes in cultures, although low 10-50 nM and high 1-20 mM dosing ranges have also been reported. Daily oral administration is reported to prevent embryos neural tube defects at E10.5 among diabetic pregnant mice (20 mg/kg/day p.o. from E6.5 to E9.5).
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable